Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Aug 21 | 2024Lexicon Zynquista Adcom; Sesame to Offer Compounded SemaglutidePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Aug 20 | 2024Tirzepatide Three-Year Positive Pre-Diabetes and Weight-Loss Results; Medtronic CY Q2 ’24 (FY Q1 ’25) Earnings Update; Tandem iOS app update; August 19-22 CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Aug 15 | 2024Medicare Price Negotiations; Lilly Targets HCPs Promoting Compounded GLP-1RAs; Arrowhead to Advance Obesity Pipeline; New AZ Ph2 Oral GLP-1RA Obesity Trial; Rivus Ph2 HFpEF Topline Results; Zealand and Fractyl Q2 ’24 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Other Aug 15 | 2024FENIX Analysis: CGM Promotional Materials Post-ADA 2024Purchase Blast
$599
Posted in: Insulin Delivery, Other, SGLT2i Aug 13 | 2024Lilly Opens New R&D Center; Tandem t:connect iOS App Recall Update; Lexicon to Refocus Business Including Salesforce Layoffs; Novartis Loses Generic Entresto Case; Galectin Q2 ’24 EarningsPurchase Blast
$599
Posted in: Other Aug 12 | 2024Esperion and Skye Bioscience Q2 ’24 Earnings; Sernova Appoints New CEOPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery Aug 12 | 2024Insulet, Senseonics, Arrowhead, Biocon, and Akero Q2 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Other Aug 08 | 2024Altimmune, Scholar Rock, Xeris, and Viatris Q2 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other Aug 08 | 2024Lilly Raises FY Guidance by $3B; Lilly Q2 ’24 Earnings; Novo Q2 ’24 London EventPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Aug 07 | 2024Abbott/Medtronic Strategic Partnership; Simplera Updates; Madrigal and MannKind Q2 ’24 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other Aug 07 | 2024STEP HFpEF Withdrawn; QM GLP/GIP Withdrawn; Novo Q2 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Aug 07 | 2024Amgen, Terns, and 89bio Q2 ‘24 Earnings; NeuroBo Partners for QM Obesity Asset FormulationPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, SGLT2i Aug 06 | 2024Kerendia FINEARTS-HF Topline Results; Simplera CGM Approved by FDA; Novo Initiates Second Ph3 H2H Cagrisema vs. Tirzepatide T2DM Study; Ypsomed and MTD Complete BGM Business SalePurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Aug 02 | 2024Tandem, Lexicon, and Vertex Q2 ’24 Earnings; Novartis Sues FDA Over Entresto GenericPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i Aug 02 | 2024Tirzepatide SUMMIT HFpEF Topline Results; Regeneron, Alnylam, Ionis, Teladoc, Amarin, and Biomea Q2 ’24 Earnings; Antag Increases Series A Funding for GIP Antagonism; Sanofi Expands Insulin Manufacturing in Germany; Boston Pharmaceuticals MASH UpdatesPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other Aug 01 | 2024FENIX Analysis: GLP-1RA Promotional Materials Post-ADA 2024Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Jul 30 | 2024Pfizer and Merck Q2 ’24 Earnings Updates; Fractyl Receives FDA Breakthrough Designation for Revita; NewAmsterdam Announces Ph3 HeFH Data; Liraglutide Associated with Decreased Risk of Cognitive DeclinePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Other Jul 29 | 2024Roche Ph2 Obesity Trial Observed; Altimmune Ph1 MASLD Data PublishedPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Jul 26 | 2024Dexcom Q2 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jul 25 | 2024Wegovy SELECT Positive CHMP Opinion; AZ, Viking, Roche, and Sanofi Q2 ’24 Earnings UpdatesPurchase Blast